Latest News by Industry
Lexington, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced it will showcase its latest medical technology advancements and portfolio of medical imaging solutions at the 2022 Radiological Society of North America ( RSNA ) annual meeting, booth #1929, held November 27 - December 1 at McCormick Place in Chicago.
For the first time at RSNA, attendees will get to experience the following new medical innovations from Fujifilm:
Fujifilm’s diagnostic imaging experts will also give booth visitors an update on additional new medical technologies that are pending regulatory approval in the U.S., including:
“When healthcare professionals are trying to diagnose medical conditions, imaging can provide a more accurate picture of what is going on inside the patient’s body. The detailed images from these scans show doctors where damage or abnormalities are, making it critical that they are using the best equipment,” said Henry Izawa, president and chief executive officer of FUJIFILM Healthcare Americas Corporation. “We’re looking forward to meeting with RSNA attendees to demonstrate how our cutting-edge solutions offer a powerful combination of high image quality and easy-to-use features, empowering clinicians to feel confident in their diagnosis and treatment plans for their patients.”
To learn more about Fujifilm’s presence at RSNA 2022 and to schedule an on-site meeting, please click here.
_______________________________________________________________________________________
*Technologies with an asterisk will be available in the U.S. upon completion of regulatory requirements.
About Fujifilm
FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis and treatment of diseases. Fujifilm’s innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery. The award-winning Synapse® Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record. Fujifilm’s AI initiative, REiLI®, combines Fujifilm’s rich image-processing heritage with cutting-edge AI innovations to inspire clinical confidence and combat burnout. The In-Vitro Diagnostic portfolio provides the gold standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information please visit healthcaresolutions-us.fujifilm.com
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030 , click here.
For the year ended March 31, 2022, the company had global revenues of approximately 2.5 trillion yen (21 billion $USD at an exchange rate of 122 yen/dollar). For more information, please visit: www.fujifilmholdings.com.
Marissa Confredo FUJIFILM Holdings America Corporation 914-789-8526 marissa.confredo@fujifilm.com Danielle Brown FUJIFILM Holdings America Corporation 914-574-3273 danielle.brown@fujifilm.com